Unveiling 13 Analyst Insights On Neurocrine Biosciences

Across the recent three months, 13 analysts have shared their insights on Neurocrine Biosciences NBIX, expressing a variety of opinions spanning from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $127.54, with a high estimate of $150.00 and a low estimate of $100.00. Marking an increase of 4.8%, the current average surpasses the previous average price target of $121.70.

Breaking Down Analyst Ratings: A Detailed Examination

The standing of Neurocrine Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Neurocrine Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Neurocrine Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Neurocrine Biosciences analyst ratings.

All You Need to Know About Neurocrine Biosciences

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Key Indicators: Neurocrine Biosciences's Financial Health

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Positive Revenue Trend: Examining Neurocrine Biosciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 28.59% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Neurocrine Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.66%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Neurocrine Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.31% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Neurocrine Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of 3.04%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

What Are Analyst Ratings?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.